What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Acquired immunodeficiency syndrome
- Virus
Immunology, Virology, Internal medicine, Acquired immunodeficiency syndrome and Virus are his primary areas of study.
His Immunology research integrates issues from Cohort and Risk factor.
Eric S. Daar combines subjects such as Incidence and Drug resistance with his study of Virology.
His biological study spans a wide range of topics, including Gastroenterology, Efavirenz, Viral load and Emtricitabine.
His Acquired immunodeficiency syndrome research includes themes of Viral disease, Asymptomatic and Immunopathology.
Eric S. Daar interconnects Epitope, Antibody and Ex vivo in the investigation of issues within Virus.
His most cited work include:
- Antiretroviral-Drug Resistance among Patients Recently Infected with HIV (1049 citations)
- The major genetic determinants of HIV-1 control affect HLA class I peptide presentation (910 citations)
- High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. (408 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Immunology, Virology, Acquired immunodeficiency syndrome and Viral load.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Efavirenz and Emtricitabine.
Eric S. Daar has included themes like Tenofovir alafenamide, Abacavir, Reverse-transcriptase inhibitor, Abacavir/Lamivudine and Ritonavir in his Emtricitabine study.
His studies in Immunology integrate themes in fields like Cytotoxic T cell and Men who have sex with men.
His work deals with themes such as Antibody and Drug resistance, which intersect with Virology.
The various areas that Eric S. Daar examines in his Acquired immunodeficiency syndrome study include Viral disease, Psychological intervention, Substance abuse and Immunopathology.
He most often published in these fields:
- Internal medicine (35.50%)
- Immunology (35.50%)
- Virology (30.15%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (35.50%)
- Randomized controlled trial (10.31%)
- Emtricitabine (13.36%)
In recent papers he was focusing on the following fields of study:
Eric S. Daar focuses on Internal medicine, Randomized controlled trial, Emtricitabine, Men who have sex with men and Pre-exposure prophylaxis.
His work carried out in the field of Internal medicine brings together such families of science as Abacavir, Acquired immunodeficiency syndrome, Antiretroviral therapy and Oncology.
Within one scientific family, Eric S. Daar focuses on topics pertaining to Placebo under Acquired immunodeficiency syndrome, and may sometimes address concerns connected to Clinical trial.
His Randomized controlled trial study also includes fields such as
- Family medicine and related Healthcare providers, Health care, Perception and Nonprobability sampling,
- Substance abuse and related Smoking status, One year follow up, Cd4 cell count, Cigarette smoking and Immunology.
His Emtricitabine study combines topics from a wide range of disciplines, such as Regimen, Tenofovir alafenamide, Adverse effect and Phases of clinical research.
The concepts of his Men who have sex with men study are interwoven with issues in Substance use and Public health.
Between 2017 and 2021, his most popular works were:
- Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial (58 citations)
- Generalizing Evidence from Randomized Trials using Inverse Probability of Sampling Weights (51 citations)
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. (46 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Acquired immunodeficiency syndrome
- Virus
Eric S. Daar mainly investigates Internal medicine, Randomized controlled trial, Emtricitabine, Men who have sex with men and Pre-exposure prophylaxis.
His work on Odds ratio, Phases of clinical research and Methotrexate as part of general Internal medicine research is often related to Brachial artery and Multicenter trial, thus linking different fields of science.
His research in Randomized controlled trial intersects with topics in Causal inference, Estimator and External validity.
His Emtricitabine research is multidisciplinary, incorporating perspectives in Abacavir, Regimen, Darunavir, Reverse-transcriptase inhibitor and Ritonavir.
His Men who have sex with men research is multidisciplinary, relying on both Logistic regression and Public health.
The Pre-exposure prophylaxis study combines topics in areas such as Clinical endpoint, Dosing, Statistical significance and Confidence interval.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
